Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

NO /RUNX3/Kynurenine Metabolic Signaling Enhances Disease Aggressiveness in Pancreatic Cancer.

Wang L, Tang W, Yang S, He P, Wang J, Gaedcke J, Strobel P, Azizian A, Ried T, Gaida MM, Yfantis HG, Lee DH, Lal A, Van den Eynde BJ, Alexander HR, Ghadimi BM, Hanna N, Hussain SP.

Int J Cancer. 2019 Oct 14. doi: 10.1002/ijc.32733. [Epub ahead of print]

PMID:
31609478
2.

Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development.

Balligand T, Achouri Y, Pecquet C, Gaudray G, Colau D, Hug E, Rahmani Y, Stroobant V, Plo I, Vainchenker W, Kralovics R, Van den Eynde BJ, Defour JP, Constantinescu SN.

Leukemia. 2019 Aug 30. doi: 10.1038/s41375-019-0538-1. [Epub ahead of print]

PMID:
31471561
3.

Identifying Antigens Recognized by Cytolytic T Lymphocytes on Tumors.

Vigneron N, Stroobant V, Ma W, Michaux A, Van den Eynde BJ.

Methods Mol Biol. 2019;1988:159-186. doi: 10.1007/978-1-4939-9450-2_13.

PMID:
31147940
4.

Influenza A Virus Infection Induces Viral and Cellular Defective Ribosomal Products Encoded by Alternative Reading Frames.

Zanker DJ, Oveissi S, Tscharke DC, Duan M, Wan S, Zhang X, Xiao K, Mifsud NA, Gibbs J, Izzard L, Dlugolenski D, Faou P, Laurie KL, Vigneron N, Barr IG, Stambas J, Van den Eynde BJ, Bennink JR, Yewdell JW, Chen W.

J Immunol. 2019 Jun 15;202(12):3370-3380. doi: 10.4049/jimmunol.1900070. Epub 2019 May 15.

PMID:
31092636
5.

Overexpression of ubiquitin-specific peptidase 15 in systemic sclerosis fibroblasts increases response to transforming growth factor β.

Galant C, Marchandise J, Stoenoiu MS, Ducreux J, De Groof A, Pirenne S, Van den Eynde B, Houssiau FA, Lauwerys BR.

Rheumatology (Oxford). 2019 Apr 1;58(4):708-718. doi: 10.1093/rheumatology/key401.

6.

The Vacuolar Pathway of Long Peptide Cross-Presentation Can Be TAP Dependent.

Ma W, Stroobant V, Heirman C, Sun Z, Thielemans K, Mulder A, van der Bruggen P, Van den Eynde BJ.

J Immunol. 2019 Jan 15;202(2):451-459. doi: 10.4049/jimmunol.1800353. Epub 2018 Dec 17.

PMID:
30559321
7.

Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.

Mandarano M, Bellezza G, Belladonna ML, Van den Eynde BJ, Chiari R, Vannucci J, Mondanelli G, Ludovini V, Ferri I, Bianconi F, Del Sordo R, Cagini L, Albini E, Metro G, Puma F, Sidoni A.

Virchows Arch. 2019 Feb;474(2):159-168. doi: 10.1007/s00428-018-2483-1. Epub 2018 Nov 17.

PMID:
30448912
8.

Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism.

Zhu J, Petit PF, Van den Eynde BJ.

Cancer Immunol Immunother. 2019 May;68(5):835-847. doi: 10.1007/s00262-018-2269-y. Epub 2018 Nov 7. Review.

PMID:
30406374
9.

Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma.

Lopes A, Vanvarenberg K, Kos Š, Lucas S, Colau D, Van den Eynde B, Préat V, Vandermeulen G.

Sci Rep. 2018 Oct 24;8(1):15732. doi: 10.1038/s41598-018-33933-7.

10.

Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.

Gomes B, Driessens G, Bartlett D, Cai D, Cauwenberghs S, Crosignani S, Dalvie D, Denies S, Dillon CP, Fantin VR, Guo J, Letellier MC, Li W, Maegley K, Marillier R, Miller N, Pirson R, Rabolli V, Ray C, Streiner N, Torti VR, Tsaparikos K, Van den Eynde BJ, Wythes M, Yao LC, Zheng X, Tumang J, Kraus M.

Mol Cancer Ther. 2018 Dec;17(12):2530-2542. doi: 10.1158/1535-7163.MCT-17-1104. Epub 2018 Sep 19.

PMID:
30232146
11.

Cytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen.

Vigneron N, Ferrari V, Van den Eynde BJ, Cresswell P, Leonhardt RM.

J Immunol. 2018 Oct 1;201(7):1875-1888. doi: 10.4049/jimmunol.1701479. Epub 2018 Aug 22.

12.

Loss of IDO1 Expression From Human Pancreatic β-Cells Precedes Their Destruction During the Development of Type 1 Diabetes.

Anquetil F, Mondanelli G, Gonzalez N, Rodriguez Calvo T, Zapardiel Gonzalo J, Krogvold L, Dahl-Jørgensen K, Van den Eynde B, Orabona C, Grohmann U, von Herrath MG.

Diabetes. 2018 Sep;67(9):1858-1866. doi: 10.2337/db17-1281. Epub 2018 Jun 26.

13.

Production of spliced peptides by the proteasome.

Vigneron N, Stroobant V, Ferrari V, Abi Habib J, Van den Eynde BJ.

Mol Immunol. 2019 Sep;113:93-102. doi: 10.1016/j.molimm.2018.03.030. Epub 2018 Apr 9.

PMID:
29650230
14.

Deficiency of immunoregulatory indoleamine 2,3-dioxygenase 1in juvenile diabetes.

Orabona C, Mondanelli G, Pallotta MT, Carvalho A, Albini E, Fallarino F, Vacca C, Volpi C, Belladonna ML, Berioli MG, Ceccarini G, Esposito SM, Scattoni R, Verrotti A, Ferretti A, De Giorgi G, Toni S, Cappa M, Matteoli MC, Bianchi R, Matino D, Iacono A, Puccetti M, Cunha C, Bicciato S, Antognelli C, Talesa VN, Chatenoud L, Fuchs D, Pilotte L, Van den Eynde B, Lemos MC, Romani L, Puccetti P, Grohmann U.

JCI Insight. 2018 Mar 22;3(6). pii: 96244. doi: 10.1172/jci.insight.96244.

15.

Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes.

Zhu J, Powis de Tenbossche CG, Cané S, Colau D, van Baren N, Lurquin C, Schmitt-Verhulst AM, Liljeström P, Uyttenhove C, Van den Eynde BJ.

Nat Commun. 2017 Nov 10;8(1):1404. doi: 10.1038/s41467-017-00784-1.

16.

Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate.

Crosignani S, Bingham P, Bottemanne P, Cannelle H, Cauwenberghs S, Cordonnier M, Dalvie D, Deroose F, Feng JL, Gomes B, Greasley S, Kaiser SE, Kraus M, Négrerie M, Maegley K, Miller N, Murray BW, Schneider M, Soloweij J, Stewart AE, Tumang J, Torti VR, Van Den Eynde B, Wythes M.

J Med Chem. 2017 Dec 14;60(23):9617-9629. doi: 10.1021/acs.jmedchem.7b00974. Epub 2017 Nov 21.

PMID:
29111717
17.

Peptide splicing by the proteasome.

Vigneron N, Ferrari V, Stroobant V, Abi Habib J, Van den Eynde BJ.

J Biol Chem. 2017 Dec 22;292(51):21170-21179. doi: 10.1074/jbc.R117.807560. Epub 2017 Nov 6. Review.

18.

Learning from the Proteasome How To Fine-Tune Cancer Immunotherapy.

Vigneron N, Abi Habib J, Van den Eynde BJ.

Trends Cancer. 2017 Oct;3(10):726-741. doi: 10.1016/j.trecan.2017.07.007. Epub 2017 Aug 24. Review.

PMID:
28958390
19.

Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8+ T cells.

Hanoteau A, Henin C, Svec D, Bisilliat Donnet C, Denanglaire S, Colau D, Romero P, Leo O, Van den Eynde B, Moser M.

Oncoimmunology. 2017 May 11;6(8):e1318234. doi: 10.1080/2162402X.2017.1318234. eCollection 2017.

20.

Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance.

Hennequart M, Pilotte L, Cane S, Hoffmann D, Stroobant V, Plaen E, Van den Eynde BJ.

Cancer Immunol Res. 2017 Aug;5(8):695-709. doi: 10.1158/2326-6066.CIR-16-0400. Epub 2017 Jul 21.

21.

Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape.

Garg AD, Coulie PG, Van den Eynde BJ, Agostinis P.

Trends Immunol. 2017 Aug;38(8):577-593. doi: 10.1016/j.it.2017.05.006. Epub 2017 Jun 10. Review.

PMID:
28610825
22.

Microenvironment Tumor Metabolic Interactions Highlighted by qMSI: Application to the Tryptophan-Kynurenine Pathway in Immuno-Oncology.

Ait-Belkacem R, Bol V, Hamm G, Schramme F, Van Den Eynde B, Poncelet L, Pamelard F, Stauber J, Gomes B.

SLAS Discov. 2017 Dec;22(10):1182-1192. doi: 10.1177/2472555217712659. Epub 2017 May 30.

PMID:
28557618
23.

The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade.

Foy JP, Bertolus C, Michallet MC, Deneuve S, Incitti R, Bendriss-Vermare N, Albaret MA, Ortiz-Cuaran S, Thomas E, Colombe A, Py C, Gadot N, Michot JP, Fayette J, Viari A, Van den Eynde B, Goudot P, Devouassoux-Shisheboran M, Puisieux A, Caux C, Zrounba P, Lantuejoul S, Saintigny P.

Ann Oncol. 2017 Aug 1;28(8):1934-1941. doi: 10.1093/annonc/mdx210.

24.

Fully automated radiosynthesis of N(1)-[(18)F]fluoroethyl-tryptophan and study of its biological activity as a new potential substrate for indoleamine 2,3-dioxygenase PET imaging.

Henrottin J, Lemaire C, Egrise D, Zervosen A, Van den Eynde B, Plenevaux A, Franci X, Goldman S, Luxen A.

Nucl Med Biol. 2016 Jun;43(6):379-89. doi: 10.1016/j.nucmedbio.2016.03.001. Epub 2016 Mar 11.

PMID:
27260779
25.

Apolipoproteins L control cell death triggered by TLR3/TRIF signaling in dendritic cells.

Uzureau S, Coquerelle C, Vermeiren C, Uzureau P, Van Acker A, Pilotte L, Monteyne D, Acolty V, Vanhollebeke B, Van den Eynde B, Pérez-Morga D, Moser M, Pays E.

Eur J Immunol. 2016 Aug;46(8):1854-66. doi: 10.1002/eji.201546252. Epub 2016 Jun 8.

26.

The Human Vaccines Project: A roadmap for cancer vaccine development.

Romero P, Banchereau J, Bhardwaj N, Cockett M, Disis ML, Dranoff G, Gilboa E, Hammond SA, Hershberg R, Korman AJ, Kvistborg P, Melief C, Mellman I, Palucka AK, Redchenko I, Robins H, Sallusto F, Schenkelberg T, Schoenberger S, Sosman J, Türeci Ö, Van den Eynde B, Koff W, Coukos G.

Sci Transl Med. 2016 Apr 13;8(334):334ps9. doi: 10.1126/scitranslmed.aaf0685. Review.

PMID:
27075624
27.

Proteasomes generate spliced epitopes by two different mechanisms and as efficiently as non-spliced epitopes.

Ebstein F, Textoris-Taube K, Keller C, Golnik R, Vigneron N, Van den Eynde BJ, Schuler-Thurner B, Schadendorf D, Lorenz FK, Uckert W, Urban S, Lehmann A, Albrecht-Koepke N, Janek K, Henklein P, Niewienda A, Kloetzel PM, Mishto M.

Sci Rep. 2016 Apr 6;6:24032. doi: 10.1038/srep24032.

28.

Long-Peptide Cross-Presentation by Human Dendritic Cells Occurs in Vacuoles by Peptide Exchange on Nascent MHC Class I Molecules.

Ma W, Zhang Y, Vigneron N, Stroobant V, Thielemans K, van der Bruggen P, Van den Eynde BJ.

J Immunol. 2016 Feb 15;196(4):1711-20. doi: 10.4049/jimmunol.1501574. Epub 2016 Jan 20.

29.

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.

Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, Coosemans A, Coulie PG, De Ruysscher D, Dini L, de Witte P, Dudek-Peric AM, Faggioni A, Fucikova J, Gaipl US, Golab J, Gougeon ML, Hamblin MR, Hemminki A, Herrmann M, Hodge JW, Kepp O, Kroemer G, Krysko DV, Land WG, Madeo F, Manfredi AA, Mattarollo SR, Maueroder C, Merendino N, Multhoff G, Pabst T, Ricci JE, Riganti C, Romano E, Rufo N, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Vacchelli E, Vandenabeele P, Vandenberk L, Van den Eynde BJ, Van Gool S, Velotti F, Zitvogel L, Agostinis P.

Front Immunol. 2015 Nov 20;6:588. doi: 10.3389/fimmu.2015.00588. eCollection 2015.

30.

Tumoral Immune Resistance Mediated by Enzymes That Degrade Tryptophan.

van Baren N, Van den Eynde BJ.

Cancer Immunol Res. 2015 Sep;3(9):978-85. doi: 10.1158/2326-6066.CIR-15-0095. Epub 2015 Aug 12. Review.

31.

The capture proteasome assay (CAPA) to evaluate subtype-specific proteasome inhibitors.

Vigneron N, Abi Habib J, Van den Eynde BJ.

Data Brief. 2015 May 18;4:146-51. doi: 10.1016/j.dib.2015.04.019. eCollection 2015 Sep.

32.

Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance.

Vigneron N, van Baren N, Van den Eynde BJ.

Oncoimmunology. 2015 Feb 3;4(5):e1003012. eCollection 2015 May.

33.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

34.

Heterogeneity of synovial molecular patterns in patients with arthritis.

Lauwerys BR, Hernández-Lobato D, Gramme P, Ducreux J, Dessy A, Focant I, Ambroise J, Bearzatto B, Nzeusseu Toukap A, Van den Eynde BJ, Elewaut D, Gala JL, Durez P, Houssiau FA, Helleputte T, Dupont P.

PLoS One. 2015 Apr 30;10(4):e0122104. doi: 10.1371/journal.pone.0122104. eCollection 2015.

35.

The capture proteasome assay: A method to measure proteasome activity in vitro.

Vigneron N, Abi Habib J, Van den Eynde BJ.

Anal Biochem. 2015 Aug 1;482:7-15. doi: 10.1016/j.ab.2015.04.019. Epub 2015 Apr 23.

PMID:
25912419
36.

microRNA-155, induced by interleukin-1ß, represses the expression of microphthalmia-associated transcription factor (MITF-M) in melanoma cells.

Arts N, Cané S, Hennequart M, Lamy J, Bommer G, Van den Eynde B, De Plaen E.

PLoS One. 2015 Apr 8;10(4):e0122517. doi: 10.1371/journal.pone.0122517. eCollection 2015.

37.

N (1)-Fluoroalkyltryptophan Analogues: Synthesis and in vitro Study as Potential Substrates for Indoleamine 2,3-Dioxygenase.

Henrottin J, Zervosen A, Lemaire C, Sapunaric F, Laurent S, Van den Eynde B, Goldman S, Plenevaux A, Luxen A.

ACS Med Chem Lett. 2015 Jan 25;6(3):260-5. doi: 10.1021/ml500385d. eCollection 2015 Mar 12.

38.

Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ.

Put K, Avau A, Brisse E, Mitera T, Put S, Proost P, Bader-Meunier B, Westhovens R, Van den Eynde BJ, Orabona C, Fallarino F, De Somer L, Tousseyn T, Quartier P, Wouters C, Matthys P.

Rheumatology (Oxford). 2015 Aug;54(8):1507-17. doi: 10.1093/rheumatology/keu524. Epub 2015 Mar 12.

PMID:
25767156
39.

Tryptophan-degrading enzymes in tumoral immune resistance.

van Baren N, Van den Eynde BJ.

Front Immunol. 2015 Feb 3;6:34. doi: 10.3389/fimmu.2015.00034. eCollection 2015. Review.

40.

Early Posttransplant Tryptophan Metabolism Predicts Long-term Outcome of Human Kidney Transplantation.

Vavrincova-Yaghi D, Seelen MA, Kema IP, Deelman LE, van der Heuvel MC, Breukelman H, Van den Eynde BJ, Henning RH, van Goor H, Sandovici M.

Transplantation. 2015 Aug;99(8):e97-104. doi: 10.1097/TP.0000000000000603.

PMID:
25651307
41.

Deciphering preferential interactions within supramolecular protein complexes: the proteasome case.

Fabre B, Lambour T, Garrigues L, Amalric F, Vigneron N, Menneteau T, Stella A, Monsarrat B, Van den Eynde B, Burlet-Schiltz O, Bousquet-Dubouch MP.

Mol Syst Biol. 2015 Jan 5;11(1):771. doi: 10.15252/msb.20145497.

42.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

43.

Proteasome subtypes and regulators in the processing of antigenic peptides presented by class I molecules of the major histocompatibility complex.

Vigneron N, Van den Eynde BJ.

Biomolecules. 2014 Nov 18;4(4):994-1025. doi: 10.3390/biom4040994. Review.

44.

Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues.

Théate I, van Baren N, Pilotte L, Moulin P, Larrieu P, Renauld JC, Hervé C, Gutierrez-Roelens I, Marbaix E, Sempoux C, Van den Eynde BJ.

Cancer Immunol Res. 2015 Feb;3(2):161-72. doi: 10.1158/2326-6066.CIR-14-0137. Epub 2014 Sep 30.

45.

Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.

Röhrig UF, Majjigapu SR, Chambon M, Bron S, Pilotte L, Colau D, Van den Eynde BJ, Turcatti G, Vogel P, Zoete V, Michielin O.

Eur J Med Chem. 2014 Sep 12;84:284-301. doi: 10.1016/j.ejmech.2014.06.078. Epub 2014 Jul 10.

PMID:
25036789
46.

Endosomal compartment: Also a dock for MHC class I peptide loading.

Ma W, Van den Eynde BJ.

Eur J Immunol. 2014 Mar;44(3):650-3. doi: 10.1002/eji.201444470.

47.

Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T.

Nat Rev Cancer. 2014 Feb;14(2):135-46. doi: 10.1038/nrc3670. Review.

PMID:
24457417
48.

A spliced antigenic peptide comprising a single spliced amino acid is produced in the proteasome by reverse splicing of a longer peptide fragment followed by trimming.

Michaux A, Larrieu P, Stroobant V, Fonteneau JF, Jotereau F, Van den Eynde BJ, Moreau-Aubry A, Vigneron N.

J Immunol. 2014 Feb 15;192(4):1962-71. doi: 10.4049/jimmunol.1302032. Epub 2014 Jan 22.

49.

Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium.

Ducreux J, Durez P, Galant C, Nzeusseu Toukap A, Van den Eynde B, Houssiau FA, Lauwerys BR.

Arthritis Rheumatol. 2014 Jan;66(1):15-23. doi: 10.1002/art.38202.

50.

Intramuscular electroporation of a P1A-encoding plasmid vaccine delays P815 mastocytoma growth.

Vandermeulen G, Uyttenhove C, De Plaen E, Van den Eynde BJ, Préat V.

Bioelectrochemistry. 2014 Dec;100:112-8. doi: 10.1016/j.bioelechem.2013.11.002. Epub 2013 Dec 1.

PMID:
24342164

Supplemental Content

Loading ...
Support Center